Alopecia areata continues to be a challenging condition to treat for many patients. Recently, there have been some significant developments with potentially dramatic impact in helping patients with the most severe cases of alopecia areata. Both involve oral medications that affect the immune system and therefore have potential side effects associated with them. Currently, there are clinical trials underway to see whether or not topical treatments can be as effective with less potential side effects. We hope to see positive results in the near future.
You Might Also Enjoy...
These are the first two CME articles on hair transplantation to ever be published in the leading peer reviewed journal in our field. I am proud to be one of its authors.
During the American Academy of Dermatology (AAD) virtual meeting experience, I was happy to participate in this very informative session on innovative therapeutic tools to slow hair loss and increase hair growth.
The New England Journal of Medicine published an interesting article on vaccine effectiveness and the need for boosters.
The attached article from the FDA outlines the medical risks associated with JAK(Janus kinase) inhibitors for the treatment of alopecia totalis and universalis.
This report gives patients a new and safe therapeutic option to treat chronic inflammatory scalp disorders like folliculitis decalvans.
Interesting article regarding study showing no surgery scars in mice.
